1991
DOI: 10.1172/jci115027
|View full text |Cite
|
Sign up to set email alerts
|

Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin.

Abstract: We studied the receptors on human cultured macrophages (MO-MO)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
75
1

Year Published

1992
1992
2020
2020

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 110 publications
(86 citation statements)
references
References 43 publications
9
75
1
Order By: Relevance
“…neoformans activates the alternative complement pathway (14,16), which results in the deposition of C3 fragments on the surface of the microorganism, mostly in the form of iC3b (15,16). iC3b acts as the major opsonic component for phagocytosis of this microorganism by phagocytic leukocytes through binding to CR3 (Mac-1) (2,17,18). In the present study, the mAb that recognizes the α chain (CD11b) of CR3 significantly suppressed the dissemination of C. neoformans from the lung to the brain.…”
Section: Resultssupporting
confidence: 48%
“…neoformans activates the alternative complement pathway (14,16), which results in the deposition of C3 fragments on the surface of the microorganism, mostly in the form of iC3b (15,16). iC3b acts as the major opsonic component for phagocytosis of this microorganism by phagocytic leukocytes through binding to CR3 (Mac-1) (2,17,18). In the present study, the mAb that recognizes the α chain (CD11b) of CR3 significantly suppressed the dissemination of C. neoformans from the lung to the brain.…”
Section: Resultssupporting
confidence: 48%
“…Importantly, the outer capsule of Cryptococcus sp. has been shown to bind with C3, a component of the alternate complement system and activates the respective pathway in vitro [40][41][42]. However, binding of C3, and thus the alternating complement activation cascade, is largely dependent on the nature and density of the capsule.…”
Section: Discussionmentioning
confidence: 99%
“…Binding of C. neoformans to MDM was determined using a modification of our previously described assay (19). MDM were incubated with C. neoformans in the presence or absence of chloroquine, using the exact same conditions as for the above antifungal activity except that the C. neoformans were labeled with rhodamine isothiocyanate (RITC) to facilitate their identification.…”
Section: Methodsmentioning
confidence: 99%
“…Our previously described Uvitex assay was used to determine the percentage of cell-associated fungi that were internalized (phagocytosed) by the MDM (19,20). Briefly, MDM and RITC-labeled C. neoformans were coincubated for 4 h as described for the binding assay.…”
Section: Methodsmentioning
confidence: 99%